Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PAM | P19021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648611 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP2D6ALOX15GRIK1GRIK2 | |
| SCHEMBL27849820 | 0.78 | CYP2D6 (0.44) | ALDH1A1CYP2D6ALOX15GRIK1GRIK2 | |
| SCHEMBL11736114 | 0.77 | TSHR (0.34) | ALOX15GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL3737342 | 0.75 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL11482992 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP2D6ALOX15PAM | |
| SCHEMBL11482990 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP2D6ALOX15PAM | |
| SCHEMBL6024479 | 0.75 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL3737344 | 0.75 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL7601030 | 0.74 | GRIK1 (0.34) | GRIK1 | |
| SCHEMBL471837 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828464-B2 | Preparation of cyclopentenones | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-07 | — | — | US | disclosed |
| US-20040102655-A1 | Preparation of cyclopentenoes | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1422212-A1 | Process for preparing cyclopentenone | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-26 | — | — | EP | disclosed |
| EP-0297447-B1 | METHOD FOR THE PREPARATION OF 2-CYCLOPENTENONES | BASF Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
| EP-0297447-A2 | Method for the preparation of 2-cyclopentenones | BASF Aktiengesellschaft (DE) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102655-A1 | Preparation of cyclopentenoes | CYP17A1, CYP2F1, CYP2S1 | ALDH1A1 389/4885CYP2D6 60/4885ALOX15 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.